XW003
Phase 3Small molecule
XW003 is one of 77 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Phase 3.
2
Indications
6
Total Trials
4
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1XW003
HHangzhou Sciwind Biosciences Co., Ltd.
Phase 3
Actemra
RochePreclinical
Amidate
PfizerPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Adenocard
AstellasPreclinical
Activella
Eli LillyPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cetrotide
EMD SeronoPreclinical
Oxycontin
PProtega
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity3 trials
Obstructive Sleep Apnea2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XW003. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details